SkinBioTherapeutics (SBTX.L)

Executive Summary

SkinBioTherapeutics is a UK-based life science company pioneering live biotherapeutic products for skin health, leveraging its proprietary SkinBiotix® platform derived from University of Manchester research. The company has commercialized a consumer supplement for psoriasis, which serves as an initial revenue stream and validates its microbiome-targeting approach. With a focus on the skin microbiome, SkinBioTherapeutics is expanding into multiple healthcare sectors, including dermatology and wound care. The company’s pipeline includes preclinical and clinical-stage candidates addressing conditions such as acne and eczema, aiming to replicate the success of its psoriasis product. As a small-cap public company (ticker: SBTX.L), SkinBioTherapeutics benefits from a low valuation (~£25M) and a focused strategy in a growing microbiome therapeutics market. The company’s financial position and stage suggest high risk but potential for significant upside if clinical milestones are achieved.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 trial results for acne candidate60% success
• Q2 2026Partnership/licensing deal for SkinBiotix platform70% success
• Q1 2027Expansion into wound care indication40% success